Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,786 articles
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares are up on Wednesday following the announcement of promising clinical results from its siRNA programs...
📰
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly...
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly...
📰
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry
New peer-reviewed article in forthcoming issue of...
📰
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...
IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC
By David Bautz, PhD
NASDAQ: IMNN
READ THE FULL IMNN RESEARCH REPORT
Business Update
Updated OVATION 2 Data Shows Continued Improvement in OS
On...
NASA Ditches Lunar Gateway for $20B Moon Base — Here Are the Space Stocks Poised to Win
NASA's pivot from an orbiting lunar gateway station to a $20 billion south-pole Moon base over seven years is a major tailwind for lunar surface...
📰
If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.25% on an annualized basis producing an average annual return of...
📰
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed investor has been buying stocks trading well below their all-time highs.
📰
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed investor has been buying stocks trading well below their all-time highs.
What's Going On With bioAffinity Technologies Stock Wednesday?
bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Wednesday. The move follows an announcement regarding a new clinical...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences Corp. (NASDAQ:AVXL) shares are tumbling on Wednesday after the company announced it has withdrawn its application for marketing...
Forget Rockets — SpaceX Takes $20 Billion Telecom Giant Public
Everyone's going to call it the biggest initial public offering ever. They'll talk about rockets, Mars and Elon Musk. But they'll be...
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
📰
So-Young (SY) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.March 25, 2026, 7:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
Beam Therapeutics Inc. (NASDAQ:BEAM) shares are up during Wednesday’s premarket session following the release of promising clinical data...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
Karsan strebt mit seinen innovativen Produkten und Hightech-Lösungen einen Platz unter den Top 5 in Europa an
ISTANBUL, 24. März 2026 /PRNewswire/ -- Karsan, die weltweit führende technologieorientierte Mobilitätsmarke im Bereich des öffentlichen Nahverkehrs...
Karsan vise le Top 5 en Europe avec ses produits innovants et ses solutions haute technologie
ISTANBUL, 23 mars 2026 /PRNewswire/ -- Karsan, la marque mondiale de mobilité axée sur la technologie dans les transports publics nouvelle...
Karsan apunta a estar entre los 5 primeros de Europa
- Karsan apunta a estar entre los 5 primeros de Europa con sus productos innovadores y soluciones de alta tecnología ESTAMBUL, 23 de marzo de 2026...
SK Hynix Targets Massive US IPO To Fuel Global AI Chip Expansion
SK Hynix is pursuing a major capital raise and expanding production amid intensifying competition in the AI chip market.
U.S. IPO Plans To Fund...
📰
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering...
📰
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage...
📰
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
PARIS, FRANCE; CAMBRIDGE, Massachusetts, 25 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société...
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.